KASEY DEAN: Open Payments
NPI 1467805119 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$430 in 18 payments from 6 companies in 2025. Trend: 2023 $23 · 2024 $67 · 2025 $430
Food & beverage: $430
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $176 |
| ABBVIE INC. | 4 | $105 |
| Otsuka America Pharmaceutical, Inc. | 3 | $74 |
| Janssen Pharmaceuticals, Inc | 1 | $28 |
| Teva Pharmaceuticals USA, Inc. | 1 | $28 |
| E.R. Squibb & Sons, L.L.C. | 1 | $20 |
Products named: CAPLYTA, VRAYLAR, REXULTI, SPRAVATO, AUSTEDO XR, ABILIFY ASIMTUFII, COBENFY.
Industry payments across NV — which companies pay providers there.
